Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis.

ABSTRACT:

Background

To evaluate the impact of tanezumab on health status, non-work activities, and work productivity in a pooled analysis of two large phase 3 osteoarthritis (OA) studies.

Methods

Subcutaneous tanezumab (2.5 mg and 5 mg) was tested in double-blind, placebo-controlled, 16-week (NCT02697773) and 24-week (NCT02709486) clinical trials in patients with moderate-to-severe OA of the hip or knee. At baseline and week 16, all patients completed EQ-5D-5L and the Work Productivity and Activity Impairment-OA (WPAI-OA) activity impairment item. Those currently employed also completed WPAI-OA work time missed, impairment while working, and overall work impairment items. Between-group differences in least squares (LS) mean changes from baseline at week 16 were tested using analysis

SUBMITTER: Conaghan PG 

PROVIDER: S-EPMC8809015 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature